While we were preparing our recombinant HER2-expressing adenoviral vaccine for human testing, we performed a pilot study of vaccination of breast cancer patients with a combination of HER2 protein vaccine and lapatinib. The gene discussed is ERBB2; the disease is breast carcinoma.